Dosing: Adult Antimicrobial Dosing, Non-dialysis
| Indication | Dose | Notes |
|---|---|---|
| All Indications | 372 mg IV/PO Q8h x 6 doses (total of 48h), then 372 mg Q24h | No renal dose adjustment |
Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis
| Indication | Dose | Notes |
|---|---|---|
| All Indications | 372 mg IV/PO Q8h x 6 doses (48h), then 372 mg IV/PO Q24h | No dose adjustment in hemodialysis |
Dialysis Notes
Dialysis Notes
Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR.
General Considerations
- For assistance with therapeutic drug monitoring (TDM), see Azole TDM Reference Document.
- Review medications for potential drug interactions.
- 372 mg of isavuconazonium = 200 mg of isavuconazole.
UCSF: Restricted to ID or Antimicrobial Stewardship except:​
IV formulation: Inability to tolerate or absorb enteral medications AND one of the following:
PO capsule: One of the following:
1) Documented or suspected serious fungal infection in a patient with prolonged QTc interval​
2) Prophylaxis against fungal infections in patients on the HBC service or lung transplant service with prolonged QTc interval or concurrent QTc prolonging medications.